SAR444656 (KT-474)
ACT17841
Phase 2 small_molecule terminated
Quick answer
SAR444656 (KT-474) for Hidradenitis Suppurativa is a Phase 2 program (small_molecule) at Kymera Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kymera Therapeutics
- Indication
- Hidradenitis Suppurativa
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated